Status:
COMPLETED
Cannabinoids, Neural Synchrony, and Information Processing
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis
Psychotic Disorders
Eligibility:
All Genders
18-55 years
Phase:
EARLY_PHASE1
Brief Summary
The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG...
Eligibility Criteria
Inclusion
- Men and women aged 18 and 55 years (extremes included) on the day of the first dosing.
- Exposed to cannabis at least once.
Exclusion
- Cannabis naïve
- Positive pregnancy screen during screening
- Hearing deficits
Key Trial Info
Start Date :
February 25 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 3 2012
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00708994
Start Date
February 25 2008
End Date
December 3 2012
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516